Sistema de Salut de Catalunya
Institut Català de la Salut
[Cohen JA, Bermel RA] Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. [Grossman CI] Biogen, Cambridge, MA, USA. [Hersh CM] Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA. [Hyland M] Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. [Mowry EM] Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. [Tintorè M, Zabalza A, Montalban X] Servei de Neurologia i Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-09-07T12:14:43Z
2022-09-07T12:14:43Z
2022-06
Multiple sclerosis; SARS-COV-2 vaccination; Humoral immune response
Esclerosis múltiple; Vacunación SARS-COV-2; Respuesta inmune humoral
Esclerosi múltiple; Vacunació SARS-COV-2; Resposta immune humoral
Background: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Methods: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. Results: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group. Conclusion: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Biogen (Cambridge, MA, USA). Funding for writing and editorial support was provided by Biogen.
Artículo
Versión publicada
Inglés
Esclerosi múltiple - Tractament; Immunoglobulina G; COVID-19 (Malaltia) - Vacunació; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Immunoglobulin Isotypes::Immunoglobulin G; DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis; CHEMICALS AND DRUGS::Complex Mixtures::Biological Products::Vaccines::Viral Vaccines; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::isotipos de inmunoglobulinas::inmunoglobulina G; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple; COMPUESTOS QUÍMICOS Y DROGAS::mezclas complejas::productos biológicos::vacunas::vacunas víricas
SAGE Publications
Multiple sclerosis Journal;28(7)
https://doi.org/10.1177/13524585211061343
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - CEMCAT [136]
Articles científics - HVH [3396]
